Bente Glintborg

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Bente Glintborg, Inge Juul Sørensen, Anne Gitte Loft et al. · Annals of the Rheumatic Diseases · 2017 · 249 citations

Medicine, Clinical Sciences, Internal Medicine +17

Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti–tumor necrosis factor α therapy: Results from the nationwide Danish DANBIO registry

Bente Glintborg, Mikkel Østergaard, Lene Dreyer et al. · Arthritis & Rheumatism · 2010 · 245 citations

Medicine, Internal Medicine, Pharmacotherapy +17

Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry

Bente Glintborg, Mikkel Østergaard, Niels Steen Krogh et al. · Annals of the Rheumatic Diseases · 2010 · 224 citations

Medicine, Immunology, Pharmacotherapy +13

Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor α Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry

Bente Glintborg, Mikkel Østergaard, Niels Steen Krogh et al. · Arthritis & Rheumatism · 2013 · 203 citations

Medicine, Immunology, Pharmacotherapy +11

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

Bente Glintborg, Anne Gitte Loft, Emina Omerovic et al. · Annals of the Rheumatic Diseases · 2018 · 155 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14